DOCSLIB.ORG

Nattokinase, Streptokinase and Urokinase) from Bacterial Sources

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nattokinase, Streptokinase and Urokinase) from Bacterial Sources African Journal of Biotechnology Vol. 10(8), pp. 1408-1420, 21 February, 2011 Available online at http://www.academicjournals.org/AJB DOI: 10.5897/AJB10.1268 ISSN 1684–5315 © 2011 Academic Journals Full Length Research Paper Isolation, production, purification, assay and characterization of fibrinolytic enzymes (Nattokinase, Streptokinase and Urokinase) from bacterial sources R. Dubey*, J. Kumar, D. Agrawala, T. Char and P. Pusp Biotechnology centre, Galaxy Concepts Pvt. Limited. Kolkata, India. Accepted 10 January, 2011 Nattokinase, Streptokinase and Urokinase are novel fibrinolytic enzymes which are isolated from Bacillus subtilis, β-haemolytic Streptococci and urine sample . The fibrinolytic enzyme Nattokinase, Streptokinase and Urokinase was purified from supernatant of Bacillus subtilis, β-haemolytic Streptococci and recombinant E.coli containing short fragment genomic DNA of Pseudomonas sp. Culture broth and showed thermophilic, hydrophilic, and strong fibrinolytic activity. The optimum temperature and pH of Nattokinase, Streptokinase and Urokinase were 37-55°C and 9, 27-37°C and 7 and 55°C and 9, respectively. The molecular weight of Nattokinase, Streptokinase and Urokinase was approximately 28 kDa, 47 kDa and 34 kDa, respectively, as determined by sodium dodecyl sulfate- polyacrylamide gel electrophoresis. The caseinolytic activity of Nattokinase, Streptokinase and Urokinase were 576.73 U, 467.73 U and 785.73 U, respectively, while fibrinolytic activity achieved by fibrin plate method were 10 U, 5 U and 15 U, respectively. Key words: Anticoagulant activity, submerge fermentation, fibrinolytic enzyme activity, protein fraction precipitation, casein, serum and plasminogen plate technique, enzyme thermodynamics, haemolytic activity, enzyme screening, expression system, zymography, Edman degradation. INTRODUCTION Fibrinolytic enzymes were identified and studied among physiochemical properties have been characterized. many organisms including snakes, earthworms, and bac- Fermented shrimp paste, a popular Asian seasoning, was teria: Streptococcus pyogenes, Aeromonas hydrophila, shown to have strong fibrinolytic activity. These novel Serratia E15, B. natto , Bacillus amyloliquefacens , Actino- fibrinolytic enzymes derived from traditional Asian foods mycetes and fungi: Fusarium oxysporum ; Mucor sp, are useful for thrombolytic therapy. They will provide an Armillaria mellea (Jian Sha et al, 2003). adjunct to the costly fibrinolytic enzymes that are Fibrinolytic enzymes can be found in a variety of foods, currently used in managing heart disease, since large such as Japanese Natto, Tofuyo, Korean Chungkook- quantities of enzyme can be conveniently and efficiently Jang soy sauce and edible honey mushroom. Fibrinolytic produced. In addition, these enzymes have significant enzymes have been purified from these foods and their potential for food fortification and nutraceutical applica- tions, such that their use could effectively prevent cardio- vascular diseases (Yoshinori et al., 2005). Accounts of cardiovascular diseases have become the *Corresponding author. E-mail: [email protected]. leading cause of death in the Western world (Viles et al., 2004). Many blood clot-dissolving agents, such as uro- Abbreviations: t-PA, Tissue plasminogen activator; SK, kinase, streptokinase, and tissue plasminogen activator streptokinase; NAT, nattokinase; UK, urokinase; CU, caseinolytic activity; PTC, phenyl thiocarbamoyl; TLC, thin layer (t-PA), have been utilized in clinical treatments for cardio- chromatography; PMSF, phenyl methyl sulfonyl fluoride; EDTA, vascular diseases. Hemostasis is a complex process ethylene diamine tetraacetic acid; SDS-PAGE, sodium obtained through an optimal balance between bleeding deodecyl sulphate polyacrylamide electrophoresis; BSA, bovine and blood clot formation. In an unbalanced state, fibrin serum albumin; PTH, phenylthiohydantoins. clots may not be lysed resulting in thrombosis . Thrombolytic Dubey et al. 1409 agents from various sources have been extensively nogen to form the active enzyme plasmin. It specifically investigated. Enzymes, such as urokinase, streptokinase catalyzes the cleavage of the Arg-Val bond in plasmi- and tissues plasminogen activators have been widely nogen. The active plasmin is then able to break down the used in the treatment of thrombosis. However, these fibrin polymers of blood clots. Clinically, UK is given to enzymes are often expensive, thermolabile and can patients suffering from thrombolytic disorders. Among the produce undesirable side effects (Chitte and Dey, 2000). plasminogen activators, UK provides a superior alterna- Subtilisin nattokinase (NAT) (formerly designated Sub- tive for the simple reasons of its being more potent as tilisin BSP), produced by Bacillus subtilis natto, is a compared to tissue-plasminogen activator and non- serine protease and is reported to have potent fibrinolytic antigenic by virtue of its human origin unlike strepto- activity (Nakamura, et al., 1992). Besides in vitro tests of kinase. Based on these observations, UK is a strong fibrinolytic activity, many in vivo studies had been plasminogen activator. Hence, UK, as one of the most reported (Sumi et al. 1990). Fujita et al. (1995) treated potent plasminogen activators is attracting a great deal of dogs with nattokinase by oral administration, and the attention. The mechanism of action, physico-chemical fibrinolytic activity in plasma increased and showed that properties, in vitro production, cloning and expression, subtilisin NAT could pass the rat intestinal tract and and clinical applications of UK are shown in the present dissolve the chemically induced thrombosis. Suzuki et al. study (Adinarayana et al., 2008). (1990) found that dietary supplementation of natto suppressed intimal thickening and modulated the lysis of mural thrombi after endothelial injury in rat femoral artery. MATERIALS AND METHODS Sumi et al. (1990) also reported a similar effect of dietary Bacillus natto productive protein on in vivo endogenous Isolation and Identification of microorganisms thrombolysis. Similar fibrinolytic enzyme-producing B. subtilis bacteria have also been isolated from Japanese shio- kara, Korea chungkook-jang (Banerjee et al., 2004), and B. subtilis producing Nattokinase (NK) was isolated from soil Chinese douchi. Nevertheless, it is still the most stable sample collected from various regions in Kolkata, India and and economic way to obtain protein with fibrinolytic identified by colony morphology, Gram’s staining, biochemical test B. subtilis and selective media. The identified microorganisms were stored at - activity by natto. On the basis of its food origin, 20°C. relatively strong fibrinolytic activity, stability in the gastrointestinal tract, and convenient oral administration, subtilisin NAT has advantages for commercially used β-haemolytic streptococci medicine for preventative and prolonged effects (Uversky et al., 2004). β-haemolytic streptococci with haemolytic activity was isolated from different samples of blood and biomass from infected throat. The Streptokinase is an extra cellular protein, extracted bacteria was identified by blood agar selective media, Gram’s from certain strains of beta hemolytic streptococcus. It is staining and biochemical tests. The three isolates exhibited a non-protease plasminogen activator that activates plas- streptokinase activity (SK) and stored at -20°C. minogen to plasmin, the enzyme that degrades fibrin cloth through its specific lysine binding site; it is used therefore as a drug in thrombolytic therapy (Mohammad Pseudomonas sp . et al., 2009). Streptokinase is currently used in clinical Pseudomonas sp producing Urokinase activity was isolated from medicine as a therapeutic agent in the treatment of human urine sample and identified by cetrimide agar selective thromboembolic blockages, including coronary throm- media, Gram’s staining and biochemical tests. The identified bosis (Banerjee et al., 2004; Endrogan et al., 2006). isolates were stored at -20°C. Streptokinase (SK) a group of extracellular proteins produced by a variety of streptococci beta-hemolytic Screening of enzymes strains, and is a plasminogen activator composed of 414 amino acids with a molecular mass of 47 kDa. Unlike uro- Screenings of fibrinolytic enzymes was done using nutrient agar kinase or tissue-type plasminogen activator that performs medium containing 2% casein and 2 ml human serum. direct proteolysis, SK forms a high affinity equimolar complex with a plasminogen (Kim et al., 2000). Urokinase (UK) is given to patients suffering from Enzyme production thrombolyticdisorders like deep vein thrombosis, Nattokinase thrombosis of the eye, pulmonary embolism, and myo- cardial infarction. This enzyme is a strong plasminogen B. subtilis was grown on basal medium containing (g/lit.) Soya activator which specifically cleaves the proenzyme/ Peptone, 10. K 2HPO 4, 2. MgSO 4, 1. Maltose, 20. Yeast extract, 10. zymogen plasminogen to form the active enzyme plasmin Glucose, 2. and 1000 ml distilled water. The pH was adjusted to 7.2 with 2 M acetic acid and 2 M NaOH. Medium was sterilized by (Kunamneni et al., 2008). UK is a serine protease, which autoclaving at 121°C for 35 min and cooled to room temperature. specifically cleaves the proenzyme/zymogen plasmi- One ml of uniformly prepared suspension of B. subtilis was used as 1410 Afr. J. Biotechnol. an inoculum; incubated at 37°C and 150 rpm in an orbital shaker. saturation. The protein fraction was precipitated with 85% ammo-
Load more

Recommended publications
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • Urokinase, a Promising Candidate for Fibrinolytic Therapy for Intracerebral Hemorrhage
    LABORATORY INVESTIGATION J Neurosurg 126:548–557, 2017 Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage *Qiang Tan, MD,1 Qianwei Chen, MD1 Yin Niu, MD,1 Zhou Feng, MD,1 Lin Li, MD,1 Yihao Tao, MD,1 Jun Tang, MD,1 Liming Yang, MD,1 Jing Guo, MD,2 Hua Feng, MD, PhD,1 Gang Zhu, MD, PhD,1 and Zhi Chen, MD, PhD1 1Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing; and 2Department of Neurosurgery, 211st Hospital of PLA, Harbin, People’s Republic of China OBJECTIVE Intracerebral hemorrhage (ICH) is associated with a high rate of mortality and severe disability, while fi- brinolysis for ICH evacuation is a possible treatment. However, reported adverse effects can counteract the benefits of fibrinolysis and limit the use of tissue-type plasminogen activator (tPA). Identifying appropriate fibrinolytics is still needed. Therefore, the authors here compared the use of urokinase-type plasminogen activator (uPA), an alternate thrombolytic, with that of tPA in a preclinical study. METHODS Intracerebral hemorrhage was induced in adult male Sprague-Dawley rats by injecting autologous blood into the caudate, followed by intraclot fibrinolysis without drainage. Rats were randomized to receive uPA, tPA, or saline within the clot. Hematoma and perihematomal edema, brain water content, Evans blue fluorescence and neurological scores, matrix metalloproteinases (MMPs), MMP mRNA, blood-brain barrier (BBB) tight junction proteins, and nuclear factor–κB (NF-κB) activation were measured to evaluate the effects of these 2 drugs in ICH. RESULTS In comparison with tPA, uPA better ameliorated brain edema and promoted an improved outcome after ICH.
    [Show full text]
  • 2-Diss Preface1
    Purification and preliminary characterization of Bothrops moojeni venom components active on haemostasis (Botmo Thesis) Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Anna Maria Perchu ć aus Warschau, Polen Referent: Prof. Dr. Beat Ernst Korreferent: Prof. Dr. phil. Jürg Meier Basel, 2010 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Herrn Prof. Dr. Beat Ernst und Herrn Prof. Dr. phil. Jürg Meier Basel, den 16. September 2008 Prof. Dr. Eberhard Parlow Dekan Wissenschaft ist der gegenwärtige Stand unseres Irrtums Jakob Franz Kern (1897-1924) Anna Maria Perchuć – Botmo Thesis I Acknowledgements To my Doktorvater Prof. Dr. Beat Ernst for his patience, support and scientific advice. To Prof. Dr. phil. Jürg Meier (my Korreferent) and to Prof. Dr. Reto Brun for their input to my PhD exam. To Pentaphatm Ltd. for giving me the opportunity to work on the “Bothrops moojeni Venom Proteomics Project”. To Marianne and Bea for helpful discussions, scientific, practical and personal support, their enthusiasm and friendship. To Reto for giving me the encouragement and guidance and for coordinating the Botmo Project. To the whole Hämostase und Test-Kit-Entwicklung Team for their friendly and helpful cooperation. To Laure, Reto, Philou and the whole Atheris Team for their scientific assistance. To Marc and his Synthesis Team for their involvement in the Botmo Project, their help, support and sense of humour. To Uwe and Andre for the fruitful cooperation. To Andreas for his great assistance and many valuable suggestions. To Remo and Martin for their support in the cell culture lab.
    [Show full text]
  • The Evolving Role of Direct Thrombin Inhibitors in Acute Coronary
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of the American College of Cardiology providedVol. by 41, Elsevier No. 4 - SupplPublisher S Connector © 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. PII S0735-1097(02)02687-6 The Evolving Role of Direct Thrombin Inhibitors in Acute Coronary Syndromes John Eikelboom, MBBS, MSC, FRACP, FRCPA,* Harvey White, MB, CHB, DSC, FRACP, FACC,† Salim Yusuf, MBBS, DPHIL, FRCP (UK), FRCPC, FACC‡ Perth, Australia; Auckland, New Zealand; and Hamilton, Ontario, Canada The central role of thrombin in the initiation and propagation of intravascular thrombus provides a strong rationale for direct thrombin inhibitors in acute coronary syndromes (ACS). Direct thrombin inhibitors are theoretically likely to be more effective than indirect thrombin inhibitors, such as unfractionated heparin or low-molecular-weight heparin, because the heparins block only circulating thrombin, whereas direct thrombin inhibitors block both circulating and clot-bound thrombin. Several initial phase 3 trials did not demonstrate a convincing benefit of direct thrombin inhibitors over unfractionated heparin. However, the Direct Thrombin Inhibitor Trialists’ Collaboration meta-analysis confirms the superiority of direct thrombin inhibitors, particularly hirudin and bivalirudin, over unfractionated heparin for the prevention of death or myocardial infarction (MI) during treatment in patients with ACS, primarily due to a reduction in MI (odds ratio, 0.80; 95% confidence interval, 0.70 to 0.91) with little impact on death. The absolute risk reduction in the composite of death or MI at the end of treatment (0.8%) was similar at 30 days (0.7%), indicating no loss of benefit after cessation of therapy.
    [Show full text]
  • J. Gen. Appl. Microbiol. Doi 10.2323/Jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation
    Advance Publication J. Gen. Appl. Microbiol. doi 10.2323/jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation 1 Genome Sequencing, Purification, and Biochemical Characterization of a 2 Strongly Fibrinolytic Enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated 3 from Chinese Traditional Douchi 4 (Received November 29, 2018; Accepted April 22, 2019; J-STAGE Advance publication date: August 14, 2019) * 5 Huilin Yang, Lin Yang, Xiang Li, Hao Li, Zongcai Tu, Xiaolan Wang 6 Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi 7 Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China * 8 Corresponding author: Xiaolan Wang, PhD, Key Lab of Protection and Utilization 9 of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 10 Ziyang Road, Nanchang 330022, China. Tel: 0086-791-88210391. 11 Email: [email protected]. 12 Short title: B. amyloliquefaciens fibrinolytic enzyme 13 14 * Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China. Email：[email protected] (X.Wang) 1 15 Abbreviation 16 CVDs: Cardiovascular diseases; u-PA: urokinase-type plasminogen activator; t-PA: 17 tissue plasminogen activator; PMSF: phenylmethanesulfonyl fluoride; SBTI: soybean 18 trypsin inhibitor; EDTA: ethylenediaminetetraacetic acid; TLCK: N-Tosyl-L-Lysine 19 chloromethyl ketone; TPCK: N-α-Tosyl-L-phenylalanine chloromethyl ketone; pNA: 20 p-nitroaniline; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel 21 electrophoresis; GO: Gene Ontology 2 22 23 Summary 24 A strongly fibrinolytic enzyme was purified from Bacillus amyloliquefaciens 25 Jxnuwx-1, found in Chinese traditional fermented black soya bean (douchi).
    [Show full text]
  • Streptokinase) and Streptococcal Desoxyribonuclease on Fibrinous, Purulent, and Sanguinous Pleural Exudations
    THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS William S. Tillett, Sol Sherry J Clin Invest. 1949;28(1):173-190. https://doi.org/10.1172/JCI102046. Research Article Find the latest version: https://jci.me/102046/pdf THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBO- NUCLEASE ON FIBRINOUS, PURULENT, AND SAN- GUINOUS PLEURAL EXUDATIONS' By WILLIAM S. TILLETT AND SOL SHERRY (From the Department of Medicine, New York University College of Medicine, and the Third Medical Division of Bellevue Hospital, New York City) (Received for publication August 6, 1948) The results described in this article were ob- coccal groups C and G (3). The product is tained by the injection of concentrated and par- abundantly excreted into the culture medium in tially purified preparations derived from broth which the organisms are grown and is readily ob- cultures of hemolytic streptococci into the pleural tainable free from the bacterial cells in sterile cavity of selected patients who were suffering filtrates. from different types of diseases that gave rise to The fibrinolytic action, in tests conducted un- pleural exudations. The possibility has been ex- der optimal laboratory conditions, is unusually plored of utilizing two of the defined properties rapid in action on the fibrin coagulum of normal elaborated by hemolytic streptococci that have the human blood, requiring only a few minutes when unique capacity of causing rapid lysis of the solid whole plasma is employed as a source of fibrin, elements (fibrin and nucleoprotein) that are sig- and an even shorter time when preparations of nificant parts of exudates.
    [Show full text]
  • Streptokinase Available Forms Indications & Dosages Interactions
    streptomycin sulfate 145 streptokinase streptomycin sulfate Kabikinase, Streptase Aminoglycoside; antibiotic Plasminogen activator; thrombolytic PRC: D enzyme PRC: C Available forms Injection: 400 mg/ml; Lyophilized cake/ Available forms powder for injection: 200 mg/ml Injection: 250,000, 750,000, 1,500,000 IU in vials for reconstitution Indications & dosages ➤ TB—Adult: 1 g or 15 mg/kg IM daily, Indications & dosages or 25-30 mg/kg (max 1.5 g) 2-3 times/wk ➤ Arteriovenous cannula occlusion— ϫ ≥ 1 yr. Elderly: Reduce daily dosage Adult: 250,000 IU in 2 ml IV solution in based on age, renal function, and 8th cra- each cannula limb over 25-35 min. Clamp nial nerve function. Suggested dosage cannula 2 hr. Aspirate, flush, and re- 10 mg/kg (max 750 mg) IM daily. Child: connect. 20-40 mg/kg (max 1 g) IM daily, or 25- ➤ Venous thrombosis, PE, arterial throm- 30 mg/kg (max 1.5 g) 2-3 times/wk ≥ bosis and embolism—Adult: 250,000 IU 1yr.† IV over 30 min. Then 100,000 IU/hr IV ϫ ➤ Enterococcal endocarditis—Adult: 1 g 72 hr for DVT and 100,000 IU/hr ϫ 24- IM q 12 hr ϫ 2 wk; then 500 mg IM q 72 hr for PE and arterial thrombosis or 12 hr ϫ 4 wk with a PCN.† embolism. ➤ Tularemia—Adult: 1-2 g IM daily in di- ➤ Lysis of coronary artery thrombi asso- vided doses ϫ 7-14 d or until patient ciated with MI—Adult: 20,000 IU IV bolus afebrile for 5-7 d.† via coronary catheter; then 2,000 IU/min ➤ Plague—Adult: 2 g (30 mg/kg) IM daily infusion over 60 min.
    [Show full text]
  • Secretion and Autoproteolytic Maturation of Subtilisin (Protein Transport/Proteolytic Processing/Mutagenesis) SCOTT D
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 3096-3100, May 1986 Biochemistry Secretion and autoproteolytic maturation of subtilisin (protein transport/proteolytic processing/mutagenesis) SCOTT D. POWER*, ROBIN M. ADAMS*, AND JAMES A. WELLSt *Department of Protein Chemistry, Genencor, Inc., 180 Kimball Way, South San Francisco, CA 94080; and tDepartment of Biocatalysis, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 Communicated by M. J. Osborn, December 19, 1985 ABSTRACT The sequence of the cloned Bacillus MATERIALS AND METHODS amyloliquefaciens subtilisin gene suggested that this secreted serine protease is produced as a larger precursor, designated T4 lysozyme was provided by Ron Wetzel (Genentech). T4 preprosubtilisin [Wells, J. A., Ferrari, E., Henner, D. J., DNA kinase was from Bethesda Research Laboratories. Estell, D. A. & Chen, E. Y. (1983) Nucleic Acids Res. 11, BamHI, EcoRI, and T4 ligase were from New England 7911-7925]. Biochemical evidence presented here shows that a Biolabs. DNA polymerase large fragment (Klenow fragment) subtilisin precursor is produced in Bacillus subtilis hosts. The was obtained from Boehringer Mannheim. Enzymes were precursor is first localized in the cell membrane, reaching a used as recommended by their respective suppliers. Eugenio steady-state level of -1000 sites per cell. Mutations in the Ferrari and Dennis Henner kindly provided the following B. subtilisin gene that alter a catalytically critical residue (i.e., subtilis strains used in these studies (6, 14): BG2036 (Apr-, aspartate +32 -* asparagine), or delete the carboxyl-terminal Npr-), BG2019 (Apr-, Npr+), BG2044 (Apr', Npr-), and portion of the enzyme that contains catalytically critical resi- I-168 (Apr', Npr+).
    [Show full text]
  • Purification and Characterization of a Subtilisin D5, a Fibrinolytic Enzyme of Bacillus Amyloliquefaciens DJ-5 Isolated from Doenjang
    Food Sci. Biotechnol. Vol. 18, No. 2, pp. 500 ~ 505 (2009) ⓒ The Korean Society of Food Science and Technology Purification and Characterization of a Subtilisin D5, a Fibrinolytic Enzyme of Bacillus amyloliquefaciens DJ-5 Isolated from Doenjang Nack-Shick Choi, Dong-Min Chung1, Yun-Jon Han, Seung-Ho Kim1, and Jae Jun Song* Enzyme Based Fusion Technology Research Team, Jeonbuk Branch Institute, Korea Research Iinstitute Bioscience & Biotechnology (KRIBB), Jeongeup, Jeonbuk 580-185, Korea 1Systemic Proteomics Research Center, Korea Research Iinstitute Bioscience & Biotechnology (KRIBB), Daejeon 305-333, Korea Abstract The fibrinolytic enzyme, subtilisin D5, was purified from the culture supernatant of the isolated Bacillus amyloliquefaciens DJ-5. The molecular weight of subtilisin D5 was estimated to be 30 kDa. Subtilisin D5 was optimally active at pH 10.0 and 45oC. Subtilisin D5 had high degrading activity for the Aα-chain of human fibrinogen and hydrolyzed the Bβ-chain slowly, but did not affect the γ-chain, indicating that it is an α-fibrinogenase. Subtilisin D5 was completely inhibited by phenylmethylsulfonyl fluoride, indicating that it belongs to the serine protease. The specific activity (F/C, fibrinolytic/caseinolytic activity) of subtilisin D5 was 2.37 and 3.52 times higher than those of subtilisin BPN’ and Carlsberg, respectively. Subtilisin D5 exhibited high specificity for Meo-Suc-Arg-Pro-Tyr-pNA (S-2586), a synthetic chromogenic substrate for chymotrypsin. The first 15 amino acid residues of the N-terminal sequence of subtilisin D5 are AQSVPYGISQIKAPA; this sequence is identical to that of subtilisin NAT and subtilisin E. Keywords: Bacillus amyloliquefaciens, doenjang, fibrinolytic enzyme, subtilisin D5 Introduction blood for more than 3 hr.
    [Show full text]
  • ACTIVASE (Alteplase) for Injection, for Intravenous Use Initial U.S
    Application 103172 This document contains: Label for ACTIVASE [Supplement 5203, Action Date 02/13/2015] Also available: Label for CATHFLO ACTIVASE [Supplement 5071, Action Date 01/04/2005] HIGHLIGHTS OF PRESCRIBING INFORMATION Acute Ischemic Stroke These highlights do not include all the information needed to use • Current intracranial hemorrhage. (4.1) ACTIVASE safely and effectively. See full prescribing information for • Subarachnoid hemorrhage. (4.1) ACTIVASE. Acute Myocardial Infarction or Pulmonary Embolism • History of recent stroke. (4.2) ACTIVASE (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987 -----------------------WARNINGS AND PRECAUTIONS-----------------------­ • Increases the risk of bleeding. Avoid intramuscular injections. Monitor for ---------------------------INDICATIONS AND USAGE--------------------------­ bleeding. If serious bleeding occurs, discontinue Activase. (5.1) Activase is a tissue plasminogen activator (tPA) indicated for the treatment of • Monitor patients during and for several hours after infusion for orolingual • Acute Ischemic Stroke (AIS). (1.1) angioedema. If angioedema develops, discontinue Activase. (5.2) • Acute Myocardial Infarction (AMI) to reduce mortality and incidence of • Cholesterol embolism has been reported rarely in patients treated with heart failure. (1.2) thrombolytic agents. (5.3) Limitation of Use in AMI: the risk of stroke may be greater than the benefit • Consider the risk of reembolization from the lysis of underlying deep in patients at low risk of death
    [Show full text]
  • Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain of Bacillus Subtilis
    J. Microbiol. Biotechnol. 2021. 31(2): 327–337 https://doi.org/10.4014/jmb.2008.08010 Review Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain of Bacillus subtilis Jorge Frias1*, Duarte Toubarro1, Alexandra Fraga5, Claudia Botelho2,3,4, José Teixeira2, Jorge Pedrosa5, and Nelson Simões1 1CBA – Biotechnology Centre of Azores, Faculty of Sciences and Technology, University of Azores, 9500-321 Ponta Delgada, Açores. Portugal 2CEB - Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal 3CBMA – Centre of Molecular and Environmental Biology, University of Minho, 4710-057 Braga, Portugal 4INL - International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal 5ICVS - Life and Health Research Institute, University of Minho, 4710-057 Braga, Portugal Fibrinolytic enzymes with a direct mechanism of action and safer properties are currently requested for thrombolytic therapy. This paper reports on a new enzyme capable of degrading blood clots directly without impairing blood coagulation. This enzyme is also non-cytotoxic and constitutes an alternative to other thrombolytic enzymes known to cause undesired side effects. Twenty-four Bacillus isolates were screened for production of fibrinolytic enzymes using a fibrin agar plate. Based on produced activity, isolate S127e was selected and identified as B. subtilis using the 16S rDNA gene sequence. This strain is of biotechnological interest for producing high fibrinolytic yield and consequently has potential in the industrial field. The purified fibrinolytic enzyme has a molecular mass of 27.3 kDa, a predicted pI of 6.6, and a maximal affinity for Ala-Ala-Pro-Phe. This enzyme was almost completely inhibited by chymostatin with optimal activity at 48oC and pH 7.
    [Show full text]
  • An Arabidopsis Mutant Over-Expressing Subtilase SBT4.13 Uncovers the Role of Oxidative Stress in the Inhibition of Growth by Intracellular Acidification
    International Journal of Molecular Sciences Article An Arabidopsis Mutant Over-Expressing Subtilase SBT4.13 Uncovers the Role of Oxidative Stress in the Inhibition of Growth by Intracellular Acidification Gaetano Bissoli 1 , Jesús Muñoz-Bertomeu 2 , Eduardo Bueso 1, Enric Sayas 1, Edgardo A. Vilcara 1, Amelia Felipo 1, Regina Niñoles 1 , Lourdes Rubio 3 , José A. Fernández 3 and Ramón Serrano 1,* 1 Instituto de Biología Molecular y Celular de Plantas, Universidad Politécnica de Valencia-Consejo Superior de Investigaciones Científicas, Camino de Vera, 46022 Valencia, Spain 2 Departament de Biologia Vegetal, Facultat de Farmàcia, Universitat de València, 46100 València, Spain 3 Departamento de Botánica y Fisiología Vegetal, Universidad de Málaga, 29071 Málaga, Spain * Correspondence: [email protected] Received: 30 January 2020; Accepted: 8 February 2020; Published: 10 February 2020 Abstract: Intracellular acid stress inhibits plant growth by unknown mechanisms and it occurs in acidic soils and as consequence of other stresses. In order to identify mechanisms of acid toxicity, we screened activation-tagging lines of Arabidopsis thaliana for tolerance to intracellular acidification induced by organic acids. A dominant mutant, sbt4.13-1D, was isolated twice and shown to over-express subtilase SBT4.13, a protease secreted into endoplasmic reticulum. Activity measurements and immuno-detection indicate that the mutant contains less plasma membrane H+-ATPase (PMA) than wild type, explaining the small size, electrical depolarization and decreased cytosolic pH of the mutant but not organic acid tolerance. Addition of acetic acid to wild-type plantlets induces production of ROS (Reactive Oxygen Species) measured by dichlorodihydrofluorescein diacetate. Acid-induced ROS production is greatly decreased in sbt4.13-1D and atrboh-D,F mutants.
    [Show full text]